Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age45-75
SponsorAustin Neuromuscular Center

About this trial

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Age ≥45 years to 75 years of age 2. Diagnosed with sIBM based on the ENMC IBM Research Diagnostic Criteria 3. Willing and able to comply with clinic visits and study-related procedures. 4. Provide informed consent signed by the study patient or legally acceptable representative.

Intravaginal

Transdermal

Oral

Disqualifiers

1. Other neurological conditions (e.g., hemiplegia post-stroke, Parkinson's Disease) or musculoskeletal conditions (e.g., severe osteoarthritis) causing mobility impairment.

Trial design

Design model

Single group

Treatments tested in this trial

  • Pozelimab/Cemdisiran

    Combination product

    Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: INJECTIONOther 1 intervention

Trial outcomes

Primary outcomes

1

IBM-Functional Rating Scale (IBM-FRS)

The IBM-FRS is a 10-item interviewer-administered patient-reported outcomes (PRO) measure that assesses physical function in patients with IBM. The IBMFRS includes items assessing lower body physical function, general physical function, the ability to perform certain activities of daily living, fine motor skills, and swallowing. On a Likert scale ranging from 0 (unable to perform activity) to 4 (normal), patients are asked to rate their difficulty in performing tasks relative to each concept before disease onset. Scores on the IBMFRS range from 0 to 40, with higher scores indicating better functioning.

Time frame
change from screening visit through week 104.
2

IBM Physical Functioning Assessment (sIFA)

The sIFA is an 11-item self-administered PRO measure assessing physical function in patients with sIBM. This questionnaire will be completed by the patient on a numeric rating scale ranging from 0 (no difficulty) to 10 (unable to do), with a total score ranging from 0 to 100, where 100 indicates severe limitations. P atients will be asked to rate their difficulty with performing tasks involving lower and upper body physical function, general physical function, fine motor skills, and swallowing in the past 7 days.

Time frame
change from screening visit through week 104.

Secondary outcomes

1

Manual Muscle Testing

This tool assesses muscle strength using a 0 - 10-point scale. A set of 7 designated muscles is tested bilaterally plus axial (neck flexor) testing so that the potential MMT-8 score ranges from 0 - 150, where a higher score indicates better functioning. The designated muscles tested will be: * Neck flexors * Deltoid middle * Biceps brachii * Gluteus maximus or Iliopsoas * Gluteus Medius * Quadriceps * Wrist extensors * Ankle dorsiflexors

Time frame
Change from screening visit through week 104
2

Hand Grip Strength

In this test, strength is measured in both the right and left hands separately with a hand grip dynamometer. Consistent angles are maintained for each patient across the shoulder, elbow, and wrist joints. Forearm and hand placement are standardized for each participant and the forearm is supported by a flat surface. Muscle strength for this test will be assessed in kilograms (kg).

Time frame
Change from screening visit through week 104
3

Quadriceps Strength Test

In this test, strength is measured in both the right and left quadriceps with a dynamometer. Consistent 90-degree angles are maintained for each patient across the hip and knee joints in sitting position. Muscle strength for this test will be assessed in kilograms (kg).

Time frame
Change from screening visit through week 104
4

Health Assessment Questionnaire Disability Index (HAQ/HAQ-DI)

This tool consists of 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities, each containing 2 to 3 questions. Scoring includes 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to perform). The score for each section is determined by its highest score. The HAQ-DI considers the subject's use of aids, devices, or assistance in the scoring algorithm for a disability category. If either "aids/devices" and/or "assistance from another person" are checked for a disability category, the score for this category is set to "2" (much difficulty), if the original score was "0" (no difficulty) or "1" (some difficulty). The HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered. Scoring conventions are based on the Standard Disability Index of HAQ/HAQ-DI, using the 20 response items. A higher score indicates greater disability.

Time frame
Change from screening visit through week 104

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Austin Neuromuscular Center

Lead sponsor

Regeneron Pharmaceuticals

Collaborator